195 related articles for article (PubMed ID: 33229136)
1. Current status in the discovery of dual BET/HDAC inhibitors.
Ren Q; Gao W
Bioorg Med Chem Lett; 2021 Jan; 31():127671. PubMed ID: 33229136
[TBL] [Abstract][Full Text] [Related]
2. Current status in the discovery of dual BET/HDAC inhibitors.
Ren Q; Gao W
Bioorg Med Chem Lett; 2021 Apr; 38():127829. PubMed ID: 33685790
[TBL] [Abstract][Full Text] [Related]
3. Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
Zhang Z; Hou S; Chen H; Ran T; Jiang F; Bian Y; Zhang D; Zhi Y; Wang L; Zhang L; Li H; Zhang Y; Tang W; Lu T; Chen Y
Bioorg Med Chem Lett; 2016 Jun; 26(12):2931-2935. PubMed ID: 27142751
[TBL] [Abstract][Full Text] [Related]
4. Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.
Liu T; Wan Y; Xiao Y; Xia C; Duan G
J Med Chem; 2020 Sep; 63(17):8977-9002. PubMed ID: 32320239
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.
Shao M; He L; Zheng L; Huang L; Zhou Y; Wang T; Chen Y; Shen M; Wang F; Yang Z; Chen L
Bioorg Med Chem Lett; 2017 Sep; 27(17):4051-4055. PubMed ID: 28765013
[TBL] [Abstract][Full Text] [Related]
6. The discovery of colchicine-SAHA hybrids as a new class of antitumor agents.
Zhang X; Zhang J; Tong L; Luo Y; Su M; Zang Y; Li J; Lu W; Chen Y
Bioorg Med Chem; 2013 Jun; 21(11):3240-4. PubMed ID: 23602523
[TBL] [Abstract][Full Text] [Related]
7. Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
Chen J; Li Y; Zhang J; Zhang M; Wei A; Liu H; Xie Z; Ren W; Duan W; Zhang Z; Shen A; Hu Y
Eur J Med Chem; 2021 Jan; 209():112868. PubMed ID: 33077265
[TBL] [Abstract][Full Text] [Related]
8. HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
Sangwan R; Rajan R; Mandal PK
Eur J Med Chem; 2018 Oct; 158():620-706. PubMed ID: 30245394
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
10. [Synthesis and activity of some new histone deacetylases inhibitors].
Cheng YH; Guo YS; Han HZ; Wang N; Zhang GH; Guo ZR; Wu S
Yao Xue Xue Bao; 2010 Jun; 45(6):735-41. PubMed ID: 20939182
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of histone deacetylase as antitumor agents: A critical review.
Manal M; Chandrasekar MJ; Gomathi Priya J; Nanjan MJ
Bioorg Chem; 2016 Aug; 67():18-42. PubMed ID: 27239721
[TBL] [Abstract][Full Text] [Related]
12. Discovery of the first histone deacetylase 6/8 dual inhibitors.
Olson DE; Wagner FF; Kaya T; Gale JP; Aidoud N; Davoine EL; Lazzaro F; Weïwer M; Zhang YL; Holson EB
J Med Chem; 2013 Jun; 56(11):4816-20. PubMed ID: 23672185
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for the design and synthesis of selective HDAC inhibitors.
Di Micco S; Chini MG; Terracciano S; Bruno I; Riccio R; Bifulco G
Bioorg Med Chem; 2013 Jul; 21(13):3795-807. PubMed ID: 23693069
[TBL] [Abstract][Full Text] [Related]
14. Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositol-3-kinase (PI3K): Current and Future Prospects.
Rodrigues DA; Pinheiro PSM; Fraga CAM
ChemMedChem; 2021 Feb; 16(3):448-457. PubMed ID: 33049098
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis and Biological Evaluation of Novel Benzoylimidazole Derivatives as Raf and Histone Deacetylases Dual Inhibitors.
Chen X; Gong G; Chen X; Song R; Duan M; Qiao R; Jiao Y; Qi J; Chen Y; Zhu Y
Chem Pharm Bull (Tokyo); 2019; 67(10):1116-1122. PubMed ID: 31582631
[TBL] [Abstract][Full Text] [Related]
16. From natural products to HDAC inhibitors: An overview of drug discovery and design strategy.
Qiu X; Zhu L; Wang H; Tan Y; Yang Z; Yang L; Wan L
Bioorg Med Chem; 2021 Dec; 52():116510. PubMed ID: 34826681
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
Wang B; Chen X; Gao J; Su L; Zhang L; Xu H; Luan Y
Bioorg Med Chem Lett; 2019 Sep; 29(18):2638-2645. PubMed ID: 31400938
[TBL] [Abstract][Full Text] [Related]
18. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of novel isoxazole-based HDAC inhibitors.
Conti P; Tamborini L; Pinto A; Sola L; Ettari R; Mercurio C; De Micheli C
Eur J Med Chem; 2010 Sep; 45(9):4331-8. PubMed ID: 20637529
[TBL] [Abstract][Full Text] [Related]
20. Lactam-based HDAC inhibitors for anticancer chemotherapy: restoration of RUNX3 by posttranslational modification and epigenetic control.
Cho M; Choi E; Kim JH; Kim H; Kim HM; Lee JI; Hwang KC; Kim HJ; Han G
ChemMedChem; 2014 Mar; 9(3):649-56. PubMed ID: 24376239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
